Xoma NASDAQ: XOMA www.xoma.com
Founded 1981 · 131 employees on LinkedIn · 1 known investors
XOMA Royalty is a biotech royalty aggregator that acquires the economic rights to future milestone and royalty payments tied to partnered pre-commercial clinical candidates, providing sellers with non-dilutive, non-recourse funding. It serves biotech companies seeking capital to advance their internal drug candidates, holding a portfolio of 120+ assets.
Founders & leadership
Investors · 1
Competitors · 2
by search overlap
Robinhood85 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Bioworld68 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Xoma NASDAQ: XOMA www.xoma.com for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Xoma NASDAQ: XOMA www.xoma.com do?
- XOMA Royalty is a biotech royalty aggregator that acquires the economic rights to future milestone and royalty payments tied to partnered pre-commercial clinical candidates, providing sellers with non-dilutive, non-recourse funding. It serves biotech companies seeking capital to advance their internal drug candidates, holding a portfolio of 120+ assets.
- Who are Xoma NASDAQ: XOMA www.xoma.com's investors?
- Xoma NASDAQ: XOMA www.xoma.com's investors include Sanderling Ventures.